NO318920B1 - Sammensetning og anvendelse av disse for fremstilling av et farmasoytisk preparat for behandling av cancer og for stimulering av antistoffproduksjon. - Google Patents

Sammensetning og anvendelse av disse for fremstilling av et farmasoytisk preparat for behandling av cancer og for stimulering av antistoffproduksjon. Download PDF

Info

Publication number
NO318920B1
NO318920B1 NO19952914A NO952914A NO318920B1 NO 318920 B1 NO318920 B1 NO 318920B1 NO 19952914 A NO19952914 A NO 19952914A NO 952914 A NO952914 A NO 952914A NO 318920 B1 NO318920 B1 NO 318920B1
Authority
NO
Norway
Prior art keywords
patients
ganglioside
conjugate
klh
melanoma
Prior art date
Application number
NO19952914A
Other languages
English (en)
Norwegian (no)
Other versions
NO952914D0 (no
NO952914L (no
Inventor
Philip O Livingston
Friedhelm Helling
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Publication of NO952914D0 publication Critical patent/NO952914D0/no
Publication of NO952914L publication Critical patent/NO952914L/no
Publication of NO318920B1 publication Critical patent/NO318920B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO19952914A 1993-01-22 1995-07-21 Sammensetning og anvendelse av disse for fremstilling av et farmasoytisk preparat for behandling av cancer og for stimulering av antistoffproduksjon. NO318920B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US926893A 1993-01-22 1993-01-22
PCT/US1994/000757 WO1994016731A1 (fr) 1993-01-22 1994-01-21 Vaccins de conjugue ganglioside-klh avec qs-21

Publications (3)

Publication Number Publication Date
NO952914D0 NO952914D0 (no) 1995-07-21
NO952914L NO952914L (no) 1995-09-14
NO318920B1 true NO318920B1 (no) 2005-05-23

Family

ID=21736616

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19952914A NO318920B1 (no) 1993-01-22 1995-07-21 Sammensetning og anvendelse av disse for fremstilling av et farmasoytisk preparat for behandling av cancer og for stimulering av antistoffproduksjon.

Country Status (15)

Country Link
US (6) US7014856B1 (fr)
EP (2) EP1360963B1 (fr)
JP (1) JP3852945B2 (fr)
KR (1) KR100307289B1 (fr)
AT (2) ATE372783T1 (fr)
AU (1) AU685776B2 (fr)
CA (1) CA2154488C (fr)
DE (2) DE69432513T2 (fr)
DK (1) DK0680338T3 (fr)
ES (1) ES2196024T3 (fr)
FI (1) FI117668B (fr)
HU (1) HU221420B1 (fr)
NO (1) NO318920B1 (fr)
NZ (2) NZ261744A (fr)
WO (1) WO1994016731A1 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69432513T2 (de) * 1993-01-22 2003-12-24 Sloan-Kettering Institute For Cancer Research, New York Gangliosid-klh-konjugatimastoffe mit qs-21
CU22420A1 (es) * 1993-12-29 1996-01-31 Centro Inmunologia Molecular Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
US5977316A (en) * 1995-01-17 1999-11-02 The Board Of Trustees Of The University Of Kentucky Monoclonal antibody 1A7 and related polypeptides
US5612030A (en) 1995-01-17 1997-03-18 University Of Kentucky Research Foundation Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US5935821A (en) * 1995-01-17 1999-08-10 Board Of Trustees Of The University Of Kentucky Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
RU2219942C2 (ru) * 1996-02-24 2003-12-27 Берингер Ингельхайм Интернациональ Гмбх Лекарственный состав с иммуномодуляторным действием, содержащий пептиды и вспомогательные средства
AU2735397A (en) * 1996-04-22 1997-11-12 Wistar Institute Of Anatomy And Biology, The Gd2 anti-idiotypic antibodies and uses thereof
US6491919B2 (en) * 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
AUPO732997A0 (en) * 1997-06-12 1997-07-03 Csl Limited Ganglioside immunostimulating complexes and uses thereof
AU745555B2 (en) * 1997-09-25 2002-03-21 Sloan-Kettering Institute For Cancer Research Fucosyl GM1-KLH conjugate vaccine against small cell lung cancer
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
EP1903114A3 (fr) 1997-12-01 2008-07-23 Neose Technologies, Inc. Synthèse enzymatique de gangliosides
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
DE60127113T2 (de) 2000-04-25 2007-06-14 Otsuka Pharmaceutical Co., Ltd. Gd3-mimetische peptide
EP1731161B1 (fr) * 2000-12-22 2014-08-06 Lpath, Inc. Anticorps sphingosine-1-phosphate pour le traitement des maladies associées à des concentrations élevées des sphingolipides
US20060210555A1 (en) 2001-12-21 2006-09-21 Antigenics, Inc. Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
ES2294535T3 (es) * 2003-08-12 2008-04-01 Lipoxen Technologies Limited Derivados del acido polisialico.
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
EP1838348B1 (fr) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Anticorps du peptide beta-amyloide humanises utilises dans l'amelioration de la cognition
WO2006076508A2 (fr) * 2005-01-14 2006-07-20 Avax Technologies, Inc. Methode de production d'un vaccin pour le traitement du cancer
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US9274129B2 (en) * 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
US9217749B2 (en) * 2006-05-31 2015-12-22 Lpath, Inc. Immune-derived moieties reactive against lysophosphatidic acid
US8796429B2 (en) * 2006-05-31 2014-08-05 Lpath, Inc. Bioactive lipid derivatives, and methods of making and using same
US9274130B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Prevention and treatment of pain using antibodies to lysophosphatidic acid
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2009124294A2 (fr) * 2008-04-05 2009-10-08 Lpath, Inc. Compositions pharmaceutiques destinées à lier la sphingosine-1-phosphate
WO2009132082A2 (fr) * 2008-04-22 2009-10-29 Medical College Of Georgia Research Institute, Inc. Compositions immunogènes contenant des céramides et leurs méthodes d’utilisation
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US8512939B2 (en) * 2009-09-25 2013-08-20 Taiwan Semiconductor Manufacturing Company, Ltd. Photoresist stripping technique
WO2012081508A1 (fr) * 2010-12-13 2012-06-21 日本ケミカルリサーチ株式会社 Procédé de dosage d'un glycosphingolipide
CN106414472A (zh) * 2013-12-06 2017-02-15 现实制药有限公司 用于靶向癌症和产生抗体的抗神经节苷脂化合物
US9856324B2 (en) 2014-06-04 2018-01-02 MabVax Therapeutics, Inc. Human monoclonal antibodies to ganglioside GD2
US11786586B2 (en) 2016-12-23 2023-10-17 Aoa Dx Carbohydrate structures and uses thereof
CA3083059A1 (fr) 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Extraction de saponine
WO2020245207A1 (fr) * 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Purification de saponine
US20250289844A1 (en) * 2022-04-29 2025-09-18 Seneb Biosciences, Inc. Treatment of gm1 deficiencies
WO2024238940A1 (fr) * 2023-05-17 2024-11-21 Regents Of The University Of Minnesota Compositions vaccinales et leurs procédés d'utilisation
EP4780465A2 (fr) * 2023-09-19 2026-07-29 Seneb Biosciences, Inc. Formulations liposomales pour traiter des déficits de gm1

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4591552A (en) * 1982-09-29 1986-05-27 New York Blood Center, Inc. Detection of hepatitis B surface antigen (or antibody to same) with labeled synthetic peptide
US4557931A (en) 1982-12-02 1985-12-10 Regents Of The University Of California Antigenic compositions and methods for using same
US4652629A (en) * 1985-07-03 1987-03-24 The Salk Institute For Biological Studies Synthetic peptide-based anti-rabies compositions and methods
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
US5344870A (en) * 1987-12-02 1994-09-06 Alberta Research Council Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation
US5102663A (en) * 1988-10-18 1992-04-07 Sloan-Kettering Instutute For Cancer Research Vaccine for stimulating or enhancing production of antibodies against 9-O-acetyl GD3
DE3840044A1 (de) 1988-11-27 1990-06-07 Behringwerke Ag Glykosphingolipide mit kopplungsfaehiger gruppe im sphingoidanteil, ihre herstellung und verwendung
GB9001694D0 (en) * 1990-01-25 1990-03-28 Therapeutic Antibodies Inc Immunogenic compositions
DE69432513T2 (de) * 1993-01-22 2003-12-24 Sloan-Kettering Institute For Cancer Research, New York Gangliosid-klh-konjugatimastoffe mit qs-21
WO1996001903A1 (fr) 1994-07-07 1996-01-25 Immunex Corporation Proteines de fusion comprenant un gm-csf et des antigenes et leur expression dans de la levure

Also Published As

Publication number Publication date
US6967022B1 (en) 2005-11-22
US7014856B1 (en) 2006-03-21
US20060153859A1 (en) 2006-07-13
EP1360963A2 (fr) 2003-11-12
NZ314058A (en) 2000-08-25
CA2154488C (fr) 2009-10-13
HK1014659A1 (en) 1999-09-30
JP3852945B2 (ja) 2006-12-06
FI117668B (fi) 2007-01-15
KR100307289B1 (ko) 2001-12-28
CA2154488A1 (fr) 1994-08-04
DE69432513D1 (de) 2003-05-22
NO952914D0 (no) 1995-07-21
HU221420B1 (en) 2002-09-28
EP0680338A1 (fr) 1995-11-08
HU9502201D0 (en) 1995-09-28
WO1994016731A1 (fr) 1994-08-04
NZ261744A (en) 1997-03-24
DK0680338T3 (da) 2003-07-21
EP0680338A4 (fr) 1997-04-09
KR960700073A (ko) 1996-01-19
AU6092494A (en) 1994-08-15
ATE237357T1 (de) 2003-05-15
HUT72193A (en) 1996-03-28
ES2196024T3 (es) 2003-12-16
JPH08508978A (ja) 1996-09-24
ATE372783T1 (de) 2007-09-15
US6936253B1 (en) 2005-08-30
US6916476B1 (en) 2005-07-12
AU685776B2 (en) 1998-01-29
FI953529A0 (fi) 1995-07-21
EP0680338B1 (fr) 2003-04-16
EP1360963A3 (fr) 2003-12-03
EP1360963B1 (fr) 2007-09-12
NO952914L (no) 1995-09-14
DE69432513T2 (de) 2003-12-24
FI953529L (fi) 1995-09-15
US7001601B1 (en) 2006-02-21
DE69435025D1 (de) 2007-10-25

Similar Documents

Publication Publication Date Title
US6967022B1 (en) Ganglioside-KLH conjugate vaccines plus QS-21
Helling et al. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21
Livingston et al. Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma
Slovin et al. Carbohydrate vaccines as immunotherapy for cancer
Ragupathi Carbohydrate antigens as targets for active specific immunotherapy
Livingston Augmenting the immunogenicity of carbohydrate tumor antigens
Vliegenthart Carbohydrate based vaccines
US9572875B2 (en) Polyvalent conjugate vaccine for cancer
Ragupathi et al. Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines
Ragupathi et al. A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers
Song et al. Fluorine-modified sialyl-Tn-CRM197 vaccine elicits a robust immune response
AU745555B2 (en) Fucosyl GM1-KLH conjugate vaccine against small cell lung cancer
CN112089832A (zh) 一种半抗原修饰的载体蛋白及其在制备疫苗中的应用
WO2001047552A1 (fr) Vaccin a conjugue acide polysialique-klh
Helling et al. Ganglioside conjugate vaccines: Immunotherapy against tumors of neuroectodermal origin
Ritter et al. Induction of antibodies reactive with GM2 ganglioside after immunization with lipopolysaccharides from Campylobacter jejuni
AU725303B2 (en) Ganglioside-KLH conjugate vaccines with QS-21
HK1014659B (en) Ganglioside-klh conjugate vaccines with qs-21
RU2174013C2 (ru) Композиция для стимулирования или повышения продуцирования антител, которые распознают ганглиозид
Livingston et al. Carbohydrate Vaccines Against Cancer

Legal Events

Date Code Title Description
MK1K Patent expired